Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Summary

This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.

Timeline

Start

2023-03-10

Primary completion

2024-07-18

Completion

2024-07-18

Drugs

Indications